Austin Health

Title
The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen.
Publication Date
2023-12-20
Author(s)
Malta, Tathiane M
Sabedot, Thais S
Morosini, Natalia S
Datta, Indrani
Garofano, Luciano
Vallentgoed, Wies R
Varn, Frederick S
Aldape, Kenneth
D'Angelo, Fulvio
Bakas, Spyridon
Barnholtz-Sloan, Jill S
Gan, Hui K
Hasanain, Mohammad
Hau, Ann-Christin
Johnson, Kevin C
Cazacu, Simona
deCarvalho, Ana C
Khasraw, Mustafa
Kocakavuk, Emre
Kouwenhoven, Mathilde C M
Migliozzi, Simona
Niclou, Simone P
Niers, Johanna M
Ormond, D Ryan
Paek, Sun Ha
Reifenberger, Guido
Sillevis Smitt, Peter A
Smits, Marion
Stead, Lucy F
van den Bent, Martin J
Van Meir, Erwin G
Walenkamp, Annemiek
Weiss, Tobias
Weller, Michael
Westerman, Bart A
Ylstra, Bauke
Wesseling, Pieter
Lasorella, Anna
French, Pim J
Poisson, Laila M
Consortium, The Glass
Verhaak, Roel G W
Iavarone, Antonio
Noushmehr, Houtan
Type of document
Journal Article
OrcId
0000-0003-1129-5791
0000-0002-7813-483X
0000-0002-9294-9461
0000-0001-7548-9881
0000-0001-8582-0865
0000-0001-6373-7710
0000-0001-6307-016X
0000-0001-5119-7550
0000-0002-4940-4693
0000-0001-8734-6482
0000-0001-6190-9304
0000-0001-7319-8546
0000-0001-5207-101X
0000-0002-4412-2355
0000-0003-0016-5158
0000-0002-6085-4177
0000-0003-1183-4548
0000-0003-3249-9849
0000-0003-1920-0494
0000-0001-5252-4365
0000-0002-4870-8943
0000-0002-3417-9534
0000-0002-0366-8247
0000-0001-7027-2915
0000-0003-3007-8653
0000-0002-1419-9837
0000-0001-8044-6798
0000-0001-5563-2871
0000-0002-9550-4150
0000-0001-5710-5127
0000-0003-2444-7707
0000-0003-4958-8960
0000-0002-5533-9429
0000-0002-1748-174X
0000-0002-9898-9616
0000-0001-9479-3010
0000-0001-5453-5201
0000-0002-1839-5421
0000-0002-0668-9529
0000-0002-3409-6536
#PLACEHOLDER_PARENT_METADATA_VALUE#
0000-0003-2773-0436
0000-0002-0683-4634
0000-0003-4051-8114
DOI
10.1158/0008-5472.CAN-23-2093
Abstract
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histological progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neo-angiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution towards an IDHwt-like phenotype.
Link
Citation
Cancer Research 2023-12-20
Jornal Title
Cancer Research
ISSN
1538-7445

Files:

NameSizeformatDescriptionLink